Hepatitis C Relapse Leads to Gilead Woes
Because three quarters of Hepatitis C patients relapsed after stopping Gilead's GS-7977, the company's financial profile suffered.
Continue reading »Hepatitis C Treatments/Therapies
Bristol-Myers Gains Momentum with All-Oral Hep C Therapy
In a recent study, over one third of previous non-responders cleared Hepatitis C with an interferon-free combo of two Bristol-Myers experimental drugs.
Continue reading »Fast-Track Given to Hepatitis C Drug ACH-1625
Jan 9, 2012
1 Comment
Likely due to its convenient dosing, safety and tolerability, Achillion's ACH-1625 has been awarded fast-track status by FDA.
Continue reading »NS5B Polymerase Inhibitors to Begin Hep C Trials
Two Hepatitis C Phase 1 studies are set to evaluate the safety and tolerability of NS5B polymerase inhibitors from Vertex and Alios BioPharma.
Continue reading »Biotron's BIT225 Shows Strong Hep C Antiviral Activity
After three months, a Phase 2a trial of Biotron's first-in-class direct acting Hepatitis C antiviral boasted a complete viral response for 87 percent of participants.
Continue reading »Initial Hep C Data on ACH-2928 Is Encouraging
Achillion's Phase 1b Hepatitis C trial for ACH-2928, their first generation inhibitor of the NS5A protein, posted good antiviral activity, safety and tolerability results after just three days.
Continue reading »Tibotec and Bristol-Myers Team Up to Battle Hepatitis C
A collaboration between pharma giants Bristol-Myers Squibb and Tibotec has been established to investigate Daclatasvir plus TMC435 against Hepatitis C genotype 1.
Continue reading »Hep C Quickly Fades with an Oral Investigational Drug Combo
A small Japanese study shows a quick and lasting response to an interferon-free regimen of Daclatasvir and Asunaprevir.
Continue reading »Hep C Trial Reports Good Results for Alisporivir
Representing a new type of Hepatitis C drug, the debut of Alisporivir (a cyclophilin inhibitor) delivers encouraging news for interferon-free Hepatitis C treatment.
Continue reading »Boehringer's Hepatitis C Drug Candidate May Compete with the Newest Treatments
Similar to the new Hepatitis C drug Telaprevir, Boehringer's protease inhibitor could reduce total treatment time to three months and improve the chances of success in the hardest-to-treat Hep C cases.
Continue reading »
